5 Tips about Sifalimumab You Can Use Today
MI-CP151 was a phase 1b randomised, double-blind, placebo managed, dose-escalation, multicentre research To judge several intravenous doses of sifalimumab, in adult individuals with dermatomyositis or polymyositis (NCT00533091). Main trial aims were being to evaluate the protection and tolerability of sifalimumab in dermatomyositis or polymyositis